Your browser doesn't support javascript.
loading
Analysis of BRCA1 germline variants (exons 5, 11 and 20) in breast cancer families from Libya.
Elmaihub, Eanas Saleh; Alhudiri, Inas; Ramadan, Ahmad M; Eljilani, Mouna; Elzagheid, Adam; Elfagi, Fakria; Hassen, Elham.
Affiliation
  • Elmaihub ES; Department of Molecular Biology, Higher Institute of Biotechnology of Monastir, Monastir University, Monastir, Tunisia.
  • Alhudiri I; Department of Molecular Biology and Biochemistry, Faculty of Sciences, Sabratha University, Sabratha, Libya.
  • Ramadan AM; Department of Genetic Engineering, Libyan Biotechnology Research Centre, Tripoli, Libya.
  • Eljilani M; Department of Genetic Engineering, Libyan Biotechnology Research Centre, Tripoli, Libya.
  • Elzagheid A; Department of Genetic Engineering, Libyan Biotechnology Research Centre, Tripoli, Libya.
  • Elfagi F; Department of Genetic Engineering, Libyan Biotechnology Research Centre, Tripoli, Libya.
  • Hassen E; Department of Oncology, National Cancer Institute, Sabratha, Libya.
Libyan J Med ; 19(1): 2356906, 2024 Dec 31.
Article in En | MEDLINE | ID: mdl-38785139
ABSTRACT
Breast cancer (BC) is a leading cause of cancer deaths in Libyan women. BRCA1 variants differ globally due to the diversity of genetic makeup and populations history. Their distribution, prevalence, and significance in Libyans remain largely unexplored. This study investigated the characteristics and distribution of BRCA1 variants in exons 5, 11, and 20 in Libyan families with BC. Thirty-six BC patients at ≤ 45 years, between 46-50 years and with a family history of breast, ovarian, pancreatic or prostate cancer in close relatives, or with triple-negative BC, were selected from 33 unrelated families during 2018-2020 at the National Cancer Institute, Sabratha, Libya. From these 33 families, 20 women (18 BC patients and two unaffected) were screened for BRCA1 exons 5, 11 and 20 using Sanger sequencing. All families completed an epidemiology and family history questionnaire. Twenty-seven variants (26 in exon 11 and 1 in exon 20, minor allele frequency of < 0.01) were detected in 10 of 18 unrelated families (55.6%.) Among the 27 variants, 26 (96%) were heterozygous. A frameshift pathogenic variant, c.2643del, and one novel variant c.1366A>G were identified. Furthermore, seven variants with unknown clinical significance were detected c.1158T>A, c.1346C>G, c.1174C>G, c.3630 G>T, c.3599A>T, and c.3400 G>C in exon 11, and c.5244T>A in exon 20. Six variants with conflicting pathogenicity interpretations, c. 3460T>A, c. 3572 G>A, c. 3700 G>C, c. 1246C>G, c. 1344C>G, and c. 1054 G>A, were also identified. Twelve benign/likely benign variants were identified. Rare BRCA1 variants that have not been reported in North Africa were found in Libyan patients. These findings provide preliminary insights into the BRCA1 variants that could contribute to hereditary BC risk in Libyans. Further functional, computational, and population analyses are essential to determine their significance and potential impact on BC risk, which could ultimately lead to more personalized management strategies.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Exons / Germ-Line Mutation / BRCA1 Protein Limits: Adult / Female / Humans / Middle aged Country/Region as subject: Africa Language: En Journal: Libyan J Med Year: 2024 Document type: Article Affiliation country: Túnez

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Exons / Germ-Line Mutation / BRCA1 Protein Limits: Adult / Female / Humans / Middle aged Country/Region as subject: Africa Language: En Journal: Libyan J Med Year: 2024 Document type: Article Affiliation country: Túnez